Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab with Trastuzumab and Paclitaxel in HER2+ Metastatic Breast Cancer
NCT01512199Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2011
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of patritumab in HER2-positive metastatic breast cancer (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 16 weeks and Progression Free Survival at 52 weeks. Started Nov 2011; status: terminated.
02
Drugs
patritumab
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01512199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01512199.